RECURRENT ENDOMETRIAL SEROUS ADENOCARCINOMA
Clinical trials for RECURRENT ENDOMETRIAL SEROUS ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT ENDOMETRIAL SEROUS ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT ENDOMETRIAL SEROUS ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy plus chemo shows promise for Tough-to-Treat endometrial cancer
Disease control OngoingThis phase III trial tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (paclitaxel and carboplatin) helps people with advanced (stage III or IV) or recurrent endometrial cancer. About 800 participants received either the combo or chemo alone. The …
Matched conditions: RECURRENT ENDOMETRIAL SEROUS ADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo shows promise for rare uterine cancer in early trial
Disease control OngoingThis phase II trial is testing whether combining niraparib (a PARP inhibitor) and dostarlimab (an immunotherapy) can shrink or control recurrent or persistent uterine serous carcinoma. The study enrolled 8 women whose cancer had returned after standard chemotherapy. Researchers a…
Matched conditions: RECURRENT ENDOMETRIAL SEROUS ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Casey Cosgrove • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Virus therapy targets Hard-to-Treat endometrial cancer
Disease control OngoingThis early-stage trial tests a specially modified virus (VSV-hIFNbeta-NIS) given through an IV to people with advanced or recurrent endometrial cancer. The virus is designed to attack cancer cells while leaving healthy cells alone, and it includes a tracer to see where it goes in…
Matched conditions: RECURRENT ENDOMETRIAL SEROUS ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC